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Abstract 
Background: Alcohol is challenging to discuss, and patients may be reluctant to disclose drinking partly because of 
concern about being judged. This report presents an overview of the development of a medications review inter-
vention co-produced with the pharmacy profession and with patients, which breaks new ground by seeking to give 
appropriate attention to alcohol within these consultations.
Methods: This intervention was developed in a series of stages and refined through conceptual discussion, literature 
review, observational and interview studies, and consultations with advisory groups. In this study we reflect on this 
process, paying particular attention to the methods used, where lessons may inform innovations in other complex 
clinical consultations.
Results: Early work with patients and pharmacists infused the entire process with a heightened sense of the com-
plexity of consultations in everyday practice, prompting careful deliberation on the implications for intervention 
development. This required the research team to be highly responsive to both co-production inputs and data gath-
ered in formally conducted studies, and to be committed to working through the implications for intervention design. 
The intervention thus evolved significantly over time, with the greatest transformations resulting from patient and 
pharmacist co-design workshops in the second stage of the process, where pharmacists elaborated on the nature of 
the need for training in particular. The original research plans provided a helpful structure, and unanticipated issues 
for investigation emerged throughout the process. This underscored the need to engage dynamically with changing 
contexts and contents and to avoid rigid adherence to any early prescribed plan.
Conclusions: Alcohol interventions are complex and require careful developmental research. This can be a messy 
enterprise, which can nonetheless shed new insights into the challenges involved in optimising interventions, and 
how to meet them, if embraced with an attitude of openness to learning. We found that exposing our own research 
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Background
Alcohol damages health, being a cause of more than 
200 diseases, injuries and other health and social prob-
lems; it is responsible for almost 5% of deaths worldwide, 
and more than twice that proportion in Europe [1]. The 
Global Burden of Disease study found that drinking alco-
hol was the leading cause of death in 2016 for the world’s 
population aged 15–49  years, accounting for approxi-
mately 8% of all deaths [2]. Among those aged 50 or older, 
cancers accounted for a large proportion of total alcohol-
attributable deaths (approximately 27% in women and 
19% in men). Health systems across the world are con-
tending with the challenges posed by multimorbidity as 
populations age, with alcohol deeply implicated in ways 
we are only now beginning to fully understand [3]. Alco-
hol costs society much more than tobacco in purely mon-
etary terms, perhaps twice as much [4, 5], as well as being 
responsible for unquantified levels of suffering to drink-
ers, and to those around them.
Paradoxically, despite the widespread nature of such 
risks and harms, one’s own alcohol consumption is not an 
easy subject for either patients or practitioners to discuss 
within healthcare services [6]. Most studies have involved 
general practitioners where time constraints and dealing 
with multiple connected issues in consultations, uncer-
tainties about roles and how to help, the particular skills 
needed, and discomfort related to practitioners’ own 
drinking are all relevant to how such discussions unfold 
[7, 8].
Alcohol is deeply embedded in personal, family and 
community lives, including those of both patients and 
practitioners, and their views on celebration, relaxa-
tion, inhibition, and socialising. More than 30 years ago 
the Royal College of Psychiatrists published Alcohol: our 
favourite drug [9], yet alcohol is rarely clearly identified as 
a drug in contemporary policy, public, health promotion 
and clinical discourses. Alcohol’s addictive nature and 
neurotoxic effects on the brain leaves no doubt that it is 
a drug; indeed alcohol is the world’s favourite drug [10].
Alcohol can cause harm at low levels of consumption 
and there is no entirely safe dose [2]. Patterns of drink-
ing that seem unremarkable, neither being very frequent 
nor involving consumption of large quantities, are likely 
to cause harm when there are existing health problems, 
and particularly so if there are multiple chronic condi-
tions [3]. Alcohol industry bodies emphasise ‘responsible 
drinking’ of their products, focusing on the individual 
user and deflecting attention from their own roles in the 
production of the harms [11, 12]. This is similar to how 
the tobacco and gambling industries emphasise the rights 
and responsibilities of consumers using their products 
[13, 14]. This deflecting construction is also found in 
widespread injunctions from policymakers on ‘responsi-
ble drinking’ [5]. Similarly vague notions such as “mod-
erate” drinking that eschew any identification of precise 
doses, or their possible effects, are also widespread. Alco-
hol dose matters greatly in how the drug affects the body, 
especially for people with long term conditions treated 
with multiple medications.
Such constructs do not assist people to think meaning-
fully and precisely about their own drinking, or its con-
sequences, or to discuss it with someone else as a way to 
clarify one’s thinking. In countries such as England that 
rely on industry organisations for public education [15], 
this may be especially challenging. Sophisticated market-
ing campaigns shape perceptions of alcohol in positive 
ways [16–18], from childhood onwards [19], and alcohol 
is central to the social media presentation of young adult 
identities [20]. It is therefore unsurprising that alcohol is 
not an easy subject for patients and practitioners to dis-
cuss with each other.
For almost 40  years the research literature on how to 
raise the subject of alcohol and then discuss it has devel-
oped based on a paradigm established in a World Health 
Organization sponsored series of studies on screen-
ing and brief interventions in general practice [21–24]. 
This paradigm is somewhat dissolving as leading pro-
ponents of this approach seek new intervention models 
[8, 25–27], and despite early optimism, no longer regard 
any population health benefits as likely in the absence 
of wider supportive policy measures [28]. The limited 
strength of existing evidence of effectiveness in routine 
healthcare settings [8] is striking given the likely scale 
of the burden on health services, which appears under-
appreciated [3]. Implementation of screening and brief 
intervention programmes is proceeding in many coun-
tries and may help alcohol and health to be more widely 
discussed. It may also have unintended consequences. 
The nature of screening is prominent among the uncer-
tainties discussed in the research community, and it has 
been proposed that there is a “need to find smarter ways 
to initiate discussions about alcohol” [29].
plans to scrutiny resulted in changes to the intervention design that gained the confidence of different stakeholders. 
Our understanding of the methods used, and their consequences, may be bounded by the person-centred nature of 
this particular intervention.
Keywords: Alcohol, Complex interventions, Pharmacist, Brief intervention, Person-centred, Medications review
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Policy developments in many countries promote the 
potential public health function of community pharma-
cies, which presents an opportunity to extend the reach 
of brief interventions. A trial in London, however, dem-
onstrated no evidence of benefit [30], and a nested quali-
tative study identified that there was missing proof of 
concept, as participants who were risky drinkers saw no 
need for intervention; they held stereotypical ideas about 
the nature of alcohol problems, and their drinking did 
not correspond with the stereotype [31].
Rather than asking pharmacists to take on a new pub-
lic health role in delivering standalone brief interventions 
targeting only alcohol, we have developed an interven-
tion approach which integrates attention to alcohol 
within what pharmacists themselves may recognise as 
good professional practice, and which can be incorpo-
rated within routine service delivery. Alcohol is a drug 
implicated in medication adherence, safety and effective-
ness issues for many patients and is thus a legitimate sub-
ject for discussion in medicines reviews. Recognition that 
alcohol itself is not pharmacologically inert challenges 
current ideas and practice positioning drinking simply 
as a lifestyle issue separated from medication issues [32]. 
We sought to develop a novel clinical intervention that 
includes alcohol within medications reviews for people 
using multiple medications for chronic conditions who 
drink alcohol twice a week or more frequently [33]. This 
study provides an overview and critical reflection of the 
methods used.
Methods
An overview of the research process
The programme of study started from the premise that 
the intervention should be co-produced with the phar-
macy profession and with patients. In our funding appli-
cation to the U.K. National Institute of Health Research, 
we identified a range of intervention development, feasi-
bility and acceptability studies necessary to prepare the 
intervention and trial design for a definitive evaluation 
study. The pre-trial phase comprised a series of stages; 
corresponding to the production of versions of the inter-
vention as set out in Fig.  1. A patient interview study 
was undertaken with 25 patients drinking twice a week 
or more frequently and taking medications for long term 
conditions [34]. An exploratory ethnographic observa-
tional study examined routine practice among 9 practi-
tioners in 5 pharmacies, observing 31 consultations [32]. 
A scoping review of the literature on the particular ser-
vices being studied [35] also preceded the development 
of Version 1 of the intervention. Then, separate co-design 
workshops with 14 patients and 7 pharmacists were 
arranged to examine Version 1 content. The intervention 
development team studied the data from the workshops, 
and synthesised it with earlier work, yielding revisions 
that redefined the intervention in Version 2. A study of 
how Version 2 of the intervention was conducted in prac-
tice resulted in Version 3, again following data synthesis 
by the team. Consultation with the research programme 
patient and pharmacist advisory groups similarly led to 
the production of Version 4. In parallel, in stages 1 and 
4 we convened theoretical and modelling discussions 
within the research team to provide a context for the 
integration of the empirical research strands. Preparation 
for each stage of the research involved detailed interven-
tion development team discussions. The planned work 
was completed on schedule after 15 months, though we 
found that during the course of intervention develop-
ment the various changes to the character and detailed 
content of the intervention generated new research 
needs. We thus embarked on a planned pilot trial under-
taken in 10 community pharmacies after Stage 4, also 
intending to do further intervention development work 
to produce an initially unplanned finalised Version 5.
The theoretical approach taken to the intervention 
development process
There are different views about complex interventions. 
In the original Medical Research Council guidance [36], 
complexity is an intrinsic property of interventions, 
which can be characterized in multiple ways, including 
the number and difficulty of the behaviours required by 
those delivering or receiving the intervention; the nature 
of the target groups and the range of possible effects; 
and the degree of flexibility or tailoring of the interven-
tion permitted. Alternatively, interventions may be con-
ceptualised as events in complex adaptive systems [37], 
and these events may themselves be simple or complex, 
directing attention towards contextual and environmen-




























Fig. 1 Overview of the 4 stages of the process
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no ‘simple’ or ‘complex’ interventions, and that simplic-
ity and complexity are instead pragmatic perspectives 
adopted by researchers to help describe and understand 
the interventions in question” [38]. Our thinking was 
much more in line with these latter two perspectives 
than the first, in keeping with a “bottom-up” data-led 
approach to co-production.
We understood that patients who participate in 
medication reviews hold their own ideas about their 
conditions, treatment, and about alcohol. We concep-
tualised drinking as posing a potential problem directly 
via its impact on health and well-being, and indirectly 
by potentially reducing adherence to, or the safety and 
effectiveness of, medications. We drew on Leventhal’s 
Common-Sense Model of self-regulation [39], and the 
necessity/concerns framework [40], and were pragmatic 
and inductive in selecting content from different theories 
that fitted the qualitative data.
The present study: how we have sought to learn 
from the intervention development process
This study pools data from the intervention develop-
ment team discussions to produce an account of how the 
design of the intervention developed over time [41], iden-
tifying the key considerations that informed the decision-
making. It will be seen that the intervention evolved in 
fundamental ways. We then reflect on the process, with a 
view to identifying transferable findings on the interven-
tion development methods used. As we have published 
a number of the component studies, we take a different 
approach to the comprehensive account provided by 
Gaume and colleagues [42], in which all data is included 
within a single exhaustive report.
Results
How the intervention development process unfolded 
during Stage 1
The ethnographic observation study provided essen-
tial grounding in the day-to-day realities of community 
pharmacy service provision, and deepened our under-
standing of the nature of the many challenges involved in 
integrating alcohol into medication discussions [32]. The 
interview study provided proof of concept that patients 
who drank alcohol regularly were open to the idea of a 
discussion that linked alcohol to medications if this was 
well designed [34]. Many, however, thought that this was 
not very relevant to them because they did not regard 
their drinking as problematic, so we further explored 
risk perceptions [43]. A further analysis of the interview 
data examined aspects of how patients actually talked 
about drinking [44]. These studies further developed our 
appreciation of the complexities inherent in conversa-
tions about drinking. In parallel we found in our scoping 
review of medication review services, along with the 
observational work, that medication review services were 
not very person-centred, with attention to alcohol con-
sumption largely absent [45]. Although there was much 
patient-centred rhetoric, this did not extend far into 
practice in any real depth.
We started by planning to adapt existing pharmacist 
training, consultation skills models and person-centred 
practice guidelines, by highlighting alcohol. We sought 
to condense relevant content to make it user friendly 
for the pharmacist and produced a brief paper summary 
guide to how the medications review consultation could 
be conceptualised in a person-centred way to include 
alcohol, placing the main preparatory content online. 
Version 1 content gave attention to existing consultation 
skills and practice, and to alcohol and medication, role-
related material and enhanced consultation skills exer-
cises including scenarios for managing more complex 
cases and for continued professional development. The 
extensive material we developed in this stage was shared 
with our patient and pharmacy advisory groups and the 
feedback on content was positive and helpful.
The key challenge we knew we faced was how to bridge 
the gulf between everyday practice and largely online 
continuing professional development training provision 
which espoused commitment to patient-centred ideas, 
but had clear limitations in supporting actual skill acqui-
sition. We also altered the primary intervention aims 
during Stage 1; no longer specifically helping people to 
reduce their drinking and the associated risk per se, but 
now being fundamentally concerned with the relation-
ships between alcohol, the medications people were using 
and the conditions for which they were being prescribed 
in the Medicines and Alcohol Consultation (MAC).
Intervention development in stages 2–4
The co-design workshops were intended to examine the 
content of Version 1, with one large patient workshop 
(including one carer/caregiver), co-facilitated by patient 
advisory group leads, particularly useful for examining 
how consultations might begin, and the idea of alcohol as 
a drug that is appropriate for medications review discus-
sions [46].
Two smaller events for pharmacists in different geo-
graphical areas explored the training content in depth. 
It was emphasized that the MAC presented a clear con-
trast to existing practice and there was willingness to 
embrace this, though time pressures were concerning, 
particularly in busier pharmacies. It was recommended 
that the online content should be condensed as it was 
anticipated to be used in practitioners’ own time, and 
thus the capacity of pharmacists to engage deeply with 
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such material was questioned, and additional in-person 
components were recommended.
The synthesis following the workshops combined the 
various strands of earlier evidence available to us and 
these two new data sources. There were not any formal 
criteria in this or later stages of decision-making. The 
limitations of our own research plans were exposed in 
being open and responsive to both patients and prac-
titioners. Our guiding principles involved being com-
mitted to understanding the complexities and the 
challenges, and to seeking to address them as far as 
possible within our own constraints. We were thus 
highly pragmatic, with the team shifting our sense of 
what was possible based on our emerging findings, with 
the basis of our decision-making at each stage always 
documented. This could then be explained to stake-
holders in ways which gained their confidence.
Version 2 of the MAC comprised a multi-compo-
nent programme designed to achieve the consultation 
skills development needed to discuss alcohol in a per-
son-centred manner within medications reviews. This 
involved two training days implemented to underpin, 
and integrate with, the other MAC programme ele-
ments. The MAC Guide offered a simple steps structure 
which summarised how the pharmacist could flexibly 
organise the consultation to be responsive to patient 
agendas and explore possible connections between 
alcohol consumption, medicine use and health (see 
Fig.  2). Practice development outcomes were set (see 
Table 1).
In stage 3 we delivered an abbreviated version of the 
practice development programme and studied how prac-
titioners used the MAC Guide, support calls, learning 
resources and buddying opportunities. The MAC Guide 
comprised a condensed version of key messages from the 
first training day intended to support practice early on, as 
practitioners became more accustomed to the approach. 
As might be expected, there was variability in how practi-
tioners engaged with the MAC programme and delivered 
the MAC in practice, together with the demands of the 
research. As well as providing data on feasibility within 
routine practice, there were also indications of effects in 
some cases. Testimonies from practitioners about altered 
consultation practice delivered in interviews were trian-
gulated with interviews with those patients, and in some 
cases with audio-recordings. This work provided helpful 
suggestions for further, more modest content develop-
ment in Version 3.
In Stage 4 we revisited the theoretical and modelling 
work, aiming to clearly describe the MAC intervention 
components, to state causal assumptions about how the 
MAC would work, taking account of contextual fac-
tors, and thereby constructing the programme theory 
to enable faithful delivery and future replication [47]. At 
this point we used the Theoretical Domains Framework 
[48] to check the theoretical content breadth and made 
minor content adjustments having identified no major 
omissions of relevant theoretical constructs. Because the 
intervention had evolved more than anticipated during 
the course of its development, we decided that a process 
study was needed during the pilot trial in order to final-
ise the intervention and its underpinning theory. We thus 
agreed Version 4 with the patient and pharmacy advi-
sory groups, thus completing the planned intervention Fig. 2 The MAC steps
Table 1 Medicines and Alcohol Consultation (MAC) programme practice development outcomes
At the conclusion of the practice development programme, we are aiming for practitioners to:
1.Have developed deeper person-centred consultation skills including through proficient use of counselling microskills and engagement with the 
MAC steps
2.Be able to use person-centred consultation skills in routine practice to support patients in making use of services provided to benefit their health
3.Be able to integrate an appropriate degree of attention to alcohol within consultations
4.Regard it as good pharmacy consultation practice to explore medications use, conditions and alcohol in a person-centred way
5.Value medication services as providing important opportunities to help patients manage their chronic conditions, and derive the optimal benefits 
from medications prescribed
6.Have changed consultation practice away from being a quick check of narrowly medication-related issues so that it is not an information-domi-
nated process
7. Manage consultations efficiently and flexibly using the structure provided by the MAC steps
8. Be able to recognise challenging issues in practice, identifying needs for skills development, and formulate plans to address them in the context of 
CPD
9. Be confident that they are developing patient-centred consultation skills and that further close attention to practice, with support, will develop 
them further
10. Be committed to further developing patient-centred consultation skills, including using Continuing Professional Development opportunities
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development process and proceeded with the pilot trial 
[49], which provided encouraging evidence of impacts, 
whilst identifying also the challenges involved in research 
participation for community pharmacists [50]. After we 
had completed the intervention development work we 
also examined in depth our experience of the nature of 
co-production with patients in the context of the relevant 
literature [51] and further analysed the nature of profes-
sionalism among pharmacists in respect of public health 
roles [52].
The MAC programme
Version 4 of the MAC programme comprised eight 
weeks of training and practice development support and 
is summarised in Fig. 3. The first training day used inter-
active sessions with patients, and a focus on core person-
centred consultation skills, particularly open questions, 
and was supported by the additional components iden-
tified in Fig. 3 in phase 1 of the programme. There was 
distinct information provided in the MAC site content in 
phases 1 and 2, after the practitioners had completed the 
second training day. That was scheduled four weeks after 
the first workshop, and focussed on the key issues identi-
fied in early use of the MAC in practice, as well as more 
advanced person-centred skills such as reflective listen-
ing and case studies of challenging issues. Throughout, 
individually tailored practice development support site 
visits and telephone calls were offered by the MAC sup-
port team on a weekly basis, including detailed feedback 
on audio-recorded MAC consultations after training day 
2 (with patient consent). We found audio-recordings 
particularly valuable to discussions of evolving practice 
development issues, enabling a focus on specific technical 
issues for the practitioners, as well as higher level reflec-
tion on patient activity in the consultations. We decided 
not to intervene in informal processes of buddying and 
peer group support, beyond encouraging these ideas 
within the training workshops, as we were curious about 
how this approach might work in the pilot trial. Lit-
tle such activity resulted, and the lesson was drawn that 
these components need to be facilitated if retained. The 
specific skills required to integrate alcohol into consulta-
tions became less elusive to pharmacists when examined 
within recordings of their own practice, which exposed 
the dynamics of interactions. There were no formalised 
evaluations of individual practitioner’s skills, with an 
open discussion about readiness of practice for the trial 
in light of the Table 1 outcomes preferred instead.
Discussion
Our intervention was fundamentally transformed in 
using the methods we set out at the grant application 
stage. Presenting an account of intervention development 
in this way offers an opportunity to appreciate potential 
synergies between individual components, and thus how 
a complex intervention has been assembled on the basis 
of a series of planned research studies and other meth-
ods. We completed the work described here within the 
originally planned 15  months, conscious that there was 
further work to do, and as identified in the subsequent 
pilot trial, which also addressed RCT feasibility issues. 
Developing the programme theory is an ongoing pro-
cess, and major areas of uncertainty, as yet unresolved, 
include further adaptations to better meet the needs of 
sub-groups of patients and practitioners. Findings from 
qualitative process study in the pilot trial will inform this 
and further intervention design.
Our developmental approach contrasts in a number of 
informative ways with the methods used by Gaume and 
colleagues [42], though both involved an iterative quali-
tative design being applied to the development of brief 
alcohol intervention, albeit with different populations in 
Fig. 3 MAC programme overview
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different health services contexts. Gaume and colleagues 
[42] rooted their thinking much more firmly in the 
existing brief interventions literature, involved external 
experts (including the first author here) in making deci-
sions, and used formal consensus development methods. 
Our approach has drawn more extensively on primary 
qualitative studies and co-production with patients and 
practitioners. We also rested decision-making authority 
within the research team (which includes both patients 
and pharmacists). Interestingly, quite different interven-
tions have resulted from the two programmes of work, 
and with further research it will be possible to progress 
brief alcohol intervention development methods. These 
need to address common challenges intrinsic to the 
activity of seizing opportunities to explore alcohol’s role 
in reasons for presentation in different clinical contexts 
[24].
The experience of the pilot trial has been illuminat-
ing for the research team and the pharmacists taking 
part. Pharmacists were more confident in raising alcohol 
within medications reviews and had received no nega-
tive feedback from patients when doing so. They were 
also more able to use certain person-centred consultation 
skills in routine practice to varying degrees. Long stand-
ing professional habits and the busy practice context, 
however, incentivised reverting to more transactional 
and less person-centred practice. All found the change 
required sustained effort, which some embraced.
This moment also offers the opportunity to reflect on 
the research process involved in the development of this 
complex intervention. Each stage in the process has been 
valuable, sometimes in quite distinct ways, and being 
responsive to study findings and guidance from our part-
ners in co-production has meant that the experience has 
been both rewarding, enlightening and challenging for 
the researchers involved. As researchers, we have learned 
in ways that we could not have anticipated at the outset, 
and the intervention design and content has changed in 
an iterative process. It has at different times been quite 
demanding and messy, sometimes in a creative way. 
Importantly, the structure provided by the research plans 
and the associated timescales have provided a basis for 
progress. One aspect to emphasise is the cyclical nature 
of the developmental process—the more the interven-
tion is developed, the more the scope for new issues to be 
considered, perhaps until a point of saturation has been 
reached, which has not yet been achieved.
Achieving a shared understanding of the nature of the 
issues involved in developing practice takes place within 
an evolving healthcare system. Changes to NHS con-
tracting arrangements during the pilot trial involved 
the phasing out of Medicine Use Reviews in community 
pharmacies. Instead a medications review service has 
been introduced in general practice, within new organi-
sational structures known as Primary Care Networks 
[53]. The intervention we have developed has been cen-
tred on the pharmacist undertaking medications reviews 
and will be transportable to this different context, albeit 
with further preparatory study and refinement needed. 
Indeed the new service with access to the electronic 
health record and a more clinical orientation to the 
patient consultation provides an enhanced platform for 
person-centred communication, and thus a context ben-
eficial to consideration of alcohol and medications.
We now have an intervention that has been carefully 
developed that may be useful to both pharmacists and 
patients. The work already done makes a substantial con-
tribution to the call for rethinking of brief interventions 
for alcohol [8, 26], by better locating alcohol within the 
setting and service provision which the patient accesses, 
and thereby eschewing standalone decontextualized 
efforts to address drinking. In so doing, this makes a 
contribution to the forging of a new paradigm to better 
address the difficult and growing burdens of alcohol and 
multimorbidity on the NHS and other health systems, 
partly by finding relatively simple ways to navigate com-
plexity. We know much more now about how pharma-
cists might talk about alcohol when trying to help people 
protect their own health, and it is likely that the lessons 
learned from this experience are transferable to other 
healthcare professions and settings.
There are obvious study limitations of different kinds. 
In examining our own processes we may not be best 
placed to identify the flaws. This study makes a contri-
bution, however, to the wider field of complex interven-
tion development studies, where the emerging norm is 
to report on one’s own process [41]. There may be much 
more effective approaches to intervention development, 
and the MAC may yet not prove to be effective in routine 
practice, but it is not possible to know this now. After 
completing this study, we found that many of the lessons 
we drew from our experience resonated strongly with 
the messages from the wider field that have found their 
way into recent guidance [54]. Similarly, there are issues 
affecting creativity in intervention development arising 
out of research funding structural constraints seen in the 
wider literature [55] and it is difficult to identify ‘success’ 
in intervention development in advance of a trial.
Conclusions
Alcohol issues are challenging to raise and address in all 
settings. Complex intervention development research 
can be a messy enterprise, which can nonetheless shed 
new insights into the challenges involved in optimis-
ing interventions, and how to meet them. Existing guid-
ance provides a useful structure within which to organise 
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research activities focused on understanding the prac-
tice, practitioner and patient contexts for intervention 
design. We found that exposing our own research plans 
to scrutiny resulted in changes to the intervention design 
that gained the confidence of different stakeholders. This 
study may be particularly important to those develop-
ing brief interventions, and be of interest also to those 
studying alcohol and/or pharmacy practice. This study 
is also highly relevant to wider complex intervention 
development research, which may benefit from reports of 
the process as well as the outcomes of existing research 
programmes.
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